|Other Names||Kallikrein-1, Kidney/pancreas/salivary gland kallikrein, Tissue kallikrein, KLK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6320b was selected from the C-term region of human KLK1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.|
|Tissue Location||Isoform 2 is expressed in pancreas, salivary glands, kidney, colon, prostate gland, testis, spleen and the colon adenocarcinoma cell line T84.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK1 is functionally conserved in its capacity to release the vasoactive peptide, Lys-bradykinin, from low molecular weight kininogen.
Montanari, D., et al., Diabetes 54(5):1573-1580 (2005).Yin, H., et al., J. Biol. Chem. 280(9):8022-8030 (2005).Azizi, M., et al., J. Clin. Invest. 115(3):780-787 (2005).Lee-Chen, G.J., et al., Kidney Int. 65(4):1467-1472 (2004).Casalino-Matsuda, S.M., et al., J. Biol. Chem. 279(20):21606-21616 (2004).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.